Back to Screener

Healthcare

CymaBay Therapeutics, Inc.(CBAY)

Live Price

Offline

$32.48

+0.03% today

1Y Change

Window

No data

Market Cap
$3.73B
Revenue Growth
0.0%
EPS Growth
+26.7%
Dividend Yield
0.0%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

CymaBay Therapeutics, Inc. (CBAY) is a Healthcare stock with a market cap of $3.73B. The stock last traded around $32.48. Baseline metrics include revenue growth of 0.0%, EPS growth of +26.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.7%, free cash flow +13.4% with operating margin -327.2% and ROIC -24.9%. Valuation already assumes a fairly strong business story at price/sales 120.0. Stock Foundry combines CBAY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

-327.2% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report came in below the EPS bar

2024 was reported on Feb 28, 2024 with an EPS surprise of -9.4% and a revenue surprise of +42.5%.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is +26.7%, while operating margin sits near -327.2%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

CBAY

Normalized return

SPY

S&P 500

Excess Return

Relative to SPY

CBAY Max Drawdown

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CBAY and SPY.

Calendar-year return history is still loading or unavailable.
CY

Company Overview

CymaBay Therapeutics, Inc.

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
EV/EBITDA
Price/Sales
120.0
Price/Book
11.8

Growth

Revenue
0.0%
EPS
+26.7%
Free Cash Flow
+13.4%

Profitability

Gross Margin
97.8%
Operating Margin
-327.2%
Net Margin
-339.1%
ROE
-64.2%
ROIC
-24.9%

Balance Sheet

Debt/Equity
0.39
Current Ratio
10.96

Earnings Reports

📅 Last reportedFeb 28, 2024
PeriodB/MEPSEPS ΔRevenueRev Δ
Feb 28, 24
-0.35
Est -0.32
-9.4%
57.0B
Est 40.0B
+42.5%
Nov 7, 23
-0.32
Est -0.30
-6.7%
Est 310.0B
Aug 10, 23
-0.01
Est -0.21
+95.2%
31016.0B
Est 9900.0B
+213.3%
May 15, 23
-0.29
Est -0.16
-81.3%
Est 21350.0B
Mar 16, 23
-0.30
Est -0.30
0.0%
Est
Nov 14, 22
-0.28
Est -0.30
+6.7%
Est
Aug 11, 22
-0.31
Est -0.30
-3.3%
Est
May 12, 22
-0.32
Est -0.31
-3.2%
Est
Mar 17, 22
-0.34
Est -0.36
+5.6%
Est 6428.6B
Nov 10, 21
-0.33
Est -0.29
-13.8%
Est
Aug 12, 21
-0.34
Est -0.27
-25.9%
Est
May 13, 21
-0.25
Est -0.24
-4.2%
Est
Mar 25, 21
-0.23
Est -0.20
-15.0%
Est
Nov 5, 20
-0.17
Est -0.17
0.0%
Est
Aug 10, 20
-0.16
Est -0.23
+30.4%
Est
May 11, 20
-0.19
Est -0.31
+38.7%
Est

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.